Pharmaceutical Technology

NOVEMBER 21, 2022

However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR). The MHLW is currently proposing discussions on the FY2023 drug price revision.

Drug Pricing

HealthPartners

MAY 5, 2021

Understanding pharmacy benefit management and drug pricing The U.S. prescription drug supply chain is extraordinarily complex. It captures, with strong simplification, the web of stakeholders in the prescription drug market and the myriad of contractual agreements that drives the cash flows between them. The result?

Drug Pricing

Pharmaceutical Technology

NOVEMBER 21, 2022

However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR). The MHLW is currently proposing discussions on the FY2023 drug price revision.

Drug Pricing

Pharmaceutical Commerce

JUNE 13, 2025

Bill Roth Key Takeaways Price hikes, not launch prices, drove the GTN bubble. The real driver of the gross-to-net (GTN) bubble was the pharmaceutical industry's ability to raise drug prices year after year—enabled by loopholes in PBM contracts—rather than high launch prices alone.

Insurance Coverage and Processing